ABSTRACT Imatinib therapy has revolutionized the clinical course of Chronic Myeloid Leukemia. The unexpected prolonged survival raised several issues on the quality of life and on the possibility to parent childs.
Cite this paper
nullF. Stagno, P. Vigneri, M. Poidomani, S. Stella, A. Cupri, M. Massimino, L. Manzella and F. Raimondo, "Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy," Open Journal of Blood Diseases, Vol. 1 No. 1, 2011, pp. 1-2. doi: 10.4236/ojbd.2011.11001.
 D. W. Sherbenou and B. J. Druker, “Applying the Discovery of the Philadelphia Chromosome,” The Journal Clinical Investigation, Vol. 117, No. 8, 2007, pp. 2067-2074. doi:10.1172/JCI31988
 M. Deininger, S. G. O’Brien, F. Guilhot, J. M. Goldman, A. Hochhaus and T. P. Hughes, “International Rando-mized Study of Interferon versus STI571 (IRIS) 8-Year Follow-Up: Sustained Survival and Low Risk for Pro-gression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib,” Blood (ASH Annual Meeting Ab-stracts), Vol. 114, 2009, p. 1126.
 D. Marin, “Current Status of Imatinib as Frontline Therapy for Chronic Myeloid Leukemia,” Seminars Hematology, Vol. 47, No. 4, 2010, pp. 312-318.
 S. M. Pye, J. Cortes, P. Ault, A. Hatfield, H. Kantarjian and R. Pilot, “The Effects of Imatinib on Pregnancy Out-come,” Blood, Vol. 111, No. 12, 2008, pp. 5505-5508.
 S. Cole, H. Kantarjian, P. Ault and J. E. Cortés, “Suc-cessful Completion of Pregnancy in a Patient with Chronic Myeloid Leukemia without Active Intervention: A Case Report and Review of the Literature,” Clinical Lymphoma Myeloma & Leukemia, Vol. 9, No. 4, 2009, pp. 324-347.
 M. Bj?rkholm, L. Ohm and L. Stenke, “Chronic Myeloid Leukemia Presenting Late in Pregnancy. Report of a Case and a Questionnaire Reflecting Diversity in Management Options,” Annals Hematology, Vol. 88, No. 2, 2009, pp. 173-175. doi:10.1007/s00277-008-0549-x